Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial

by Vandana Singh, Benzinga Editor

August 19, 2021 9:58 AM | 1 min read |

AstraZeneca Plc's AZN bispecific antibody derived from Compugen Ltd's CGEN COM902 will advance into clinical development.
AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.
COM902 was licensed to AstraZeneca in 2018 exclusively to develop bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities.
Compugen retains all other rights to the program, except those licensed to AstraZeneca.
Price Action: CGEN shares are down 1.51% at $5.89, and AZN stock is up 0.42% at $59.69 during the market session on the last check Thursday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs Non-Small Cell Lung Cancer Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.